TECHWIRE 30
(CIX: WRAL30)  1,061.59  down arrow-0.86  (-0.08 %)  Updated: 09:32 AM EDT, Oct 22 2014
(NQ: Apple)  102.83  up arrow+0.36  (0.35 %)  Updated: 09:33 AM EDT, Oct 22 2014
(NY: QUINTILES)  56.17  down arrow-0.33  (-0.58 %)  Updated: 09:32 AM EDT, Oct 22 2014
(OP: BASF SE)  88.68  down arrow-0.33  (-0.37 %)  Updated: 09:30 AM EDT, Oct 22 2014
(NQ: BioCryst)  11.39  up arrow+0.02  (0.18 %)  Updated: 09:32 AM EDT, Oct 22 2014
(NQ: BioDelivery)  16.30  down arrow-0.05  (-0.31 %)  Updated: 09:32 AM EDT, Oct 22 2014
(NQ: CEMP)  12.04  down arrow-0.15  (-1.25 %)  Updated: 09:32 AM EDT, Oct 22 2014
(NQ: Cisco Systems)  23.61  up arrow+0.1  (0.4 %)  Updated: 09:33 AM EDT, Oct 22 2014
(NQ: Cree)  29.90  down arrow-3.25  (-9.8 %)  Updated: 09:32 AM EDT, Oct 22 2014
(NQ: DARA)  0.92  up arrow+0.05  (5.74 %)  Updated: 09:32 AM EDT, Oct 22 2014
(NY: EMC CORPORATION)  26.73  down arrow-0.47  (-1.73 %)  Updated: 09:32 AM EDT, Oct 22 2014
(NQ: Extreme Networks)  3.20    (0 %)  Updated: 09:32 AM EDT, Oct 22 2014
(NQ: FB)  78.58  down arrow-0.11  (-0.14 %)  Updated: 09:33 AM EDT, Oct 22 2014
(NY: GLAXOSMITHKLINE)  44.63  up arrow+1  (2.3 %)  Updated: 09:32 AM EDT, Oct 22 2014
(NQ: GOOG)  530.01  up arrow+3.47  (0.66 %)  Updated: 09:33 AM EDT, Oct 22 2014
(NY: IBM)  163.39  up arrow+0.16  (0.1 %)  Updated: 09:33 AM EDT, Oct 22 2014
(NY: LH)  101.19  down arrow-0.11  (-0.11 %)  Updated: 09:32 AM EDT, Oct 22 2014
(OP: Lenovo Group)  29.10  up arrow+0.08  (0.28 %)  Updated: 09:31 AM EDT, Oct 22 2014
(NY: MRK)  55.19  up arrow+0.06  (0.11 %)  Updated: 09:33 AM EDT, Oct 22 2014
(NQ: Microsoft Corp)  45.01  up arrow+0.13  (0.29 %)  Updated: 09:33 AM EDT, Oct 22 2014
(NQ: NTAP)  39.67  up arrow+0.4  (1.02 %)  Updated: 09:32 AM EDT, Oct 22 2014
(NY: NOVARTIS AG)  88.64  up arrow+0.03  (0.03 %)  Updated: 09:32 AM EDT, Oct 22 2014
(OP: Novozymes A/S)  41.08    (0 %)  Updated: 08:10 PM EDT, Oct 21 2014
(NY: PFIZER)  28.11  down arrow-0.17  (-0.6 %)  Updated: 09:33 AM EDT, Oct 22 2014
(NQ: Pozen)  8.29  up arrow+0.02  (0.24 %)  Updated: 09:30 AM EDT, Oct 22 2014
(NY: RED HAT)  56.69  down arrow-0.44  (-0.77 %)  Updated: 09:33 AM EDT, Oct 22 2014
(NQ: BBRY)  10.22  up arrow+0.07  (0.69 %)  Updated: 09:33 AM EDT, Oct 22 2014
(NQ: Salix)  141.43  up arrow+0.88  (0.63 %)  Updated: 09:32 AM EDT, Oct 22 2014
(NQ: SQI)  15.33    (0 %)  Updated: 09:30 AM EDT, Oct 22 2014

Posts tagged “BDSI”

August 6, 2012

Premium Lock BioDelivery Sciences moves closer to $30M in milestone payments

The Raleigh-based firm also terminates its vice president for business and strategic development "without cause."

BDSI's product pipeline BDSI's product pipeline

May 21, 2012

Premium Lock BioDelivery Sciences receives $2.5M milestone payment

BDSI The Raleigh-based drug development firm will receive another $2.5 million from its partner Meda when its breakthrough pain reliever goes on sale in Europe.

April 13, 2012

Premium Lock Raleigh firm BDSI targets growing drug abuse, addiction markets

BioDelivery Sciences plans to file a new drug application for its opioid dependence treatment BEMA Buprenorphine in the first half of 2013.

How BDSI technology works How BDSI technology works

Updated March 13, 2012

Premium Lock FDA concerns lead to delay in BDSI cancer drug relaunch

How BDSI technology works Over Onsolis' two-year shelf life, the product's pink appearance can fade. The FDA told the Raleigh company that the color change could confuse patients and the agency is directing BDSI to make formulation changes.

March 8, 2012

Premium Lock BioDelivery Sciences makes clean sweep in patent fight

How BDSI technology works The U.S. Patent and Trademark Office has rejected all claims made by MonoSol Rx in the third MonoSol patent that the New Jersey company alleged BDSI had infringed. In total, MonoSol had made 222 claims covering three of its patents.

Updated March 6, 2012

Premium Lock Triangle news: Bandwidth.com; BioDelivery Sciences; SAS; Precision BioSciences; Novella Clinical; SlickEdit

Tech briefs Bandwidth.com division Inetwork expands management team; BDSI says it prevails in patent fight; SAS makes knowledge management firm list; Precision files patent suit; Noval Clinical division adds new exec; SlickEdit to tout software to gamers.

February 23, 2012

Premium Lock Raleigh-based BioDelivery Sciences prevails in patent fight

Specialty pharmaceutical company BDSI says the USPTO has rejected all of the claims asserted by rival MonoSol in the latest patent claim. Both companies have technologies that deliver drugs via a small piece of film that dissolves in the mouth.

How BDSI technology works How BDSI technology works

February 16, 2012

Premium Lock Raleigh-based BDSI secures patent, $15M payment

BDSI BioDelivery Sciences' patent for its drug delivery technology triggers a milestone payment from its partner Endo Pharmaceuticals.

February 6, 2012

Premium Lock Raleigh-based BioDelivery Sciences gears to raise $40M

BDSI The Raleigh-based specialty pharmaceutical company has filed a shelf registration that would allow BDSI to raise up to $40 million by selling stock if it needs the money.

Updated January 6, 2012

Premium Lock BioDelivery Sciences strikes license deal worth up to $180M

The Raleigh-based company receives an upfront payment of $30 million from Endo Pharmaceuticals for rights to its treatment technology for chronic pain.

BDSI BDSI

Updated January 2, 2012

Premium Lock FDA changes should benefit BioDelivery Sciences

Some opioid painkillers used by cancer patients are governed by U.S. Food and Drug Administration plans to manage possible health risks. The FDA is changing how it manages these drugs and these changes should help BDSI.

BDSI BDSI

November 29, 2011

Premium Lock BioDelivery Sciences scores victory in patent dispute

BDSI The US Patent and Trademark Office has rejected all 191 claims made by New Jersey-based MonoSol Rx as unpatentable. The dispute centers on the technology that forms BDSI's drug delivery platform.

November 16, 2011

Premium Lock BioDelivery Sciences runs short on cash, time

Painkillers The company has $15.1 million in cash. But the Raleigh-based firm is working on two clinical-stage drug programs and it doesn't have enough money to pay for both of them.

Updated November 11, 2011

Premium Lock Raleigh drug firm BDSI takes aim at $1B opioid drug market

BDSI "We believe we are on course to become one of the first products to compete with Suboxone, a product with sales in excess of a billion dollars annually and currently without competition," CEO Mark Sirgo says.

September 29, 2011

Premium Lock BioDelivery Sciences not phased by drug's trial failure

BDSI The Raleigh-based company also says potential partners are still interested in the pain reliver.

September 29, 2011

Premium Lock BioDelivery Sciences drug candidate fails in trial

BDSI The chronic pain reliver didn't perform better than a placebo in a Phase 3 clinical trial, but the Raleigh company isn'r giving up.

August 24, 2011

Premium Lock BioDelivery Sciences prepares for launch of pain killer in Canada

BDSI The Raleigh-based drug firm gears to sell breakthrough cancer pain reliver after working through production problems.

October 20, 2010

Premium Lock BioDelivery Sciences secures European approval for pain killer

BDSI The decision means $2.5 million in milestone payment for the Raleigh firm.

Techwire Inside Partners
The Skinny: A Blog by Rick Smith

OUR INSIDERS

Dr. Mike Walden
Tech economy
Vivek Wadhwa
Commentary
Frank Vinluan
Life science
Scroll